Femara Dragon Pharma

Description

Femara (Letrozole) 100 tabs (2.5 mg/tab) – Oral Steroids from Dragon Pharma.

Antitumor non-steroidal preparation, specific inhibitor of aromatase enzyme. Competitive binding to the subunit of the aromatase enzyme involved in estrogen synthesis eliminates the stimulating effect of the latter on tumor growth. It helps to suppress tumor growth.
In a common form of breast cancer during the postmenopausal period, daily use of letrosol results in a 75-95% decrease in estradiol, estrone sulfate, and estrone in the blood. At the same time, in these women the level of androstendion does not change. That is, the blockade of estrogen biosynthesis does not entail the accumulation of androgens, which are precursors to estrogens. Also, the concentrations of luteinizing and follicle-stimulating hormones and thyroid hormones do not change.

The drug does not affect the synthesis of steroid hormones in the adrenal glands, so there is no need to correct glucocorticoids and mineralocorticoids.

Pharmacokinetics

Letrosol is quickly absorbed from the LCD. Bioavailability of 99.9%. Eating slightly reduces absorption. It binds 60% to blood proteins. Equilibrium concentration is achieved in 3-6 weeks under the condition of daily intake in a normal dose. Cumulation is noted. Letrosol is metabolized to form an inactive compound. It is excreted as metabolites by the kidneys and through the intestine.